<div style="margin: 12px 0px; font-family: arial; color: #333333; background: #ffffff; border: solid 4px #e5e5e5; width: 100%; clear: left;"><div class="CM_CTB_Content_Wrap" style="margin: 0px; padding: 0px;background-color: #ffffff;"><div style="border-bottom: solid 1px #dcdcdc; white-space: nowrap; margin-bottom: 8px; background-color: #eeeeee ;background-image: url(http://www.clipmarks.com/images/source-bg.gif); background-repeat: repeat-x; height: 24px; line-height: 24px; vertical-align: middle; padding-bottom: 4px; color: #666666; font-size: 10px;" ><a href="http://clipmarks.com/clip-to-blog/" title="see clips that are hot right now"><img src="http://content.clipmarks.com/blog_embed/ccb998d6-a356-40f5-b128-d9423a8637b8/D8930A5A-DDEF-4D7E-AFC8-79D9FC50CC16/" alt="" width="19" height="19" border="0" style="vertical-align: middle; margin: 0px 4px; display: inline; border: none; float:none;" /></a>clipped from <a title="http://general-medicine.jwatch.org/cgi/content/full/2007/815/3" href="http://general-medicine.jwatch.org/cgi/content/full/2007/815/3" style="font-size: 11px;">general-medicine.jwatch.org</a></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://general-medicine.jwatch.org/cgi/content/full/2007/815/3"><UL><li style="margin-left:16px;padding-left: 0px;">Total spending on DTC advertising in the U.S. increased from about $1 billion in 1996 to $4 billion in 2005; DTC advertising represented about 14% of drug company promotional expenditures in 2005. </LI><li style="margin-left:16px;padding-left: 0px;">DTC advertising consumed about one third of the total marketing budgets for proton-pump inhibitors, statins, and erythropoietin in 2005. The five single drugs with the highest expenditures for DTC advertising were Nexium, Lunesta, Vytorin, Crestor, and Advair. </LI><li style="margin-left:16px;padding-left: 0px;">From 2002 to 2006, DTC advertising was the target of one third to one half of letters sent by the FDA to drug companies regarding violations in regulations on drug promotion. Most citations were for DTC advertising that minimized risks or exaggerated effectiveness. </LI><li style="margin-left:16px;padding-left: 0px;">The authors suggest that the level of FDA staffing dedicated to review of DTC advertising has not kept pace with the recent increase in DTC advertising. </LI></UL></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://general-medicine.jwatch.org/cgi/content/full/2007/815/3"><P class="citations">Donohue JM et al. A decade of direct-to-consumer advertising of prescription drugs. <I>N Engl J Med</I> 2007 Aug 16; 357:673-81.</P></blockquote></div><div style="margin: 0px 6px 6px 4px;"><table style="font-size: 11px;border-spacing: 0px;padding: 0px;" cellpadding="0" cellspacing="0" width="100%"><tr><td style="background:transparent;border-width:0px;padding:0px;">&nbsp;</td><td align="right" style="background:transparent;border-width:0px;padding:0px;width:107px" width="107"><a href="http://clipmarks.com/share/D8930A5A-DDEF-4D7E-AFC8-79D9FC50CC16/blog/" title="blog or email this clip"><img src="http://content7.clipmarks.com/images/c2b-foot.png" border="0" alt="blog it" width="107" height="17" style="border-width:0px;padding:0px;margin:0px;" /></a></td></tr></table></div></div>

New from the makers of Clipmarks:  Amplify.com - Don't just share the news...Amplify it!